Cellestis firms up Japanese deal
Monday, 20 October, 2003
Diagnostic company Cellestis has completed an amendment to its distribution agreement with Japanese company Nichirei, covering price and minimum volumes for its second generation TB test QuantiFERON-TB GOLD.
Cellestis managing director Dr Tony Radford said in a statement that subject to approval of the test for sale in Japan, the amended agreement has a minimum product purchase requirement in excess of AUD$2 million during the first 2 years post-approval. The company hoped its agreement with Nichirei would help it exceed its minimum volume targets, he said.
Nichirei and Cellestis submitted an application for approval to the Japanese regulatory authorities in May this year, but approval is not expected before May 2004 at the earliest.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
